Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

被引：483

作者：

Hallberg, Bengt ^{[1
]}

Palmer, Ruth H. ^{[1
]}

机构：

[1] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden

来源：

NATURE REVIEWS CANCER | 2013年 / 13卷 / 10期

基金：

瑞典研究理事会;

关键词：

ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR; NPM-ALK; LUNG-CANCER; MOLECULAR CHARACTERIZATION; DOWN-REGULATION; TRUNCATED FORM; GROWTH-FACTOR; FUSION GENE;

D O I：

10.1038/nrc3580

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.

引用

页码：685 / 700

页数：16

共 50 条

[11] Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Murray, Phillip B.
Lax, Irit
Reshetnyak, Andrey
Ligon, Gwenda F.
Lillquist, Jay S.
Natoli, Edward J., Jr.
Shi, Xiarong
Folta-Stogniew, Ewa
Gunel, Murat
Alvarado, Diego
Schlessinger, Joseph
SCIENCE SIGNALING, 2015, 8 (360)
[12] ALECTINIB HYDROCHLORIDE ALK Receptor Tyrosine Kinase Inhibitor Oncolytic
Cole, P.
DRUGS OF THE FUTURE, 2013, 38 (12) : 799 - 805
[13] Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M
Schmidt, L
Nakaigawa, N
Webb, CP
Weirich, G
Kishida, T
Zbar, B
VandeWoude, GF
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) : 11445 - 11450
[14] Kinetic and Mechanistic Characterization of a Potent and Selective Inhibitor for Human AXL Receptor Tyrosine Kinase
Chen, Yu
Miles, Dillon
Udyavar, Akshata
Cho, Sean
Becker, Annette
Foley, Corinne
Leleti, Manmohan
Jin, Lixia
Young, Stephen
Powers, Jay
Walters, Matthew
Zhao, Xiaoning
FASEB JOURNAL, 2020, 34
[15] ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
Motegi, A
Fujimoto, J
Kotani, M
Sakuraba, H
Yamamoto, T
JOURNAL OF CELL SCIENCE, 2004, 117 (15) : 3319 - 3329
[16] NADPH Oxidase Biology and the Regulation of Tyrosine Kinase Receptor Signaling and Cancer Drug Cytotoxicity
Paletta-Silva, Rafael
Rocco-Machado, Nathalia
Meyer-Fernandes, Jose Roberto
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (02): : 3683 - 3704
[17] A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist
Tolbert, W. David
Daugherty, Jennifer
Gao, ChongFeng
Xie, Qian
Miranti, Cindy
Gherardi, Ermanno
Woude, George Vande
Xu, H. Eric
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (37) : 14592 - 14597
[18] Receptor tyrosine kinase inhibitors in cancer
Nasim Ebrahimi
Elmira Fardi
Hajarossadat Ghaderi
Sahar Palizdar
Roya Khorram
Reza Vafadar
Masoud Ghanaatian
Fatemeh Rezaei-Tazangi
Payam Baziyar
Amirhossein Ahmadi
Michael R. Hamblin
Amir Reza Aref
Cellular and Molecular Life Sciences, 2023, 80
[19] Receptor tyrosine kinase inhibitors in cancer
Ebrahimi, Nasim
Fardi, Elmira
Ghaderi, Hajarossadat
Palizdar, Sahar
Khorram, Roya
Vafadar, Reza
Ghanaatian, Masoud
Rezaei-Tazangi, Fatemeh
Baziyar, Payam
Ahmadi, Amirhossein
Hamblin, Michael R.
Aref, Amir Reza
CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (04)
[20] Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
Gibson, Amanda J. W.
Box, Adrian
Dean, Michelle L.
Elegbede, Anifat A.
Hao, Desiree
Sangha, Randeep
Bebb, Gwyn
JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):

← 1 2 3 4 5 →